Abstract
Adjuvant immunotherapy with polyadenylic-polyuridylic acid (PolyA.PolyU) was tested in a randomised trial on 300 patients with operable breast cancer, all of whom were treated by surgery with or without radiotherapy. They were randomly divided into an experimental group of 155 patients who were treated with 30 mg PolyA.PolyU intravenously per week for 6 weeks and a control group of 145 patients who received normal saline intravenously on the same schedule. The mean follow-up time was more than 50 months in both groups. The overall survival was significantly higher in the treated group (p ≤ 0.05), in whom the 5-year 'relapse-free' survival was also increased. In node-positive patients, treatment increased the relapse-free survival (p ≤ 0.03) and overall survival (p ≤ 0.07). No side-effects were noted. Thus, immunotherapy with PolyA.PolyU appears to be a simple, non-toxic, and efficient adjuvant treatment in operable breast cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 161-164 |
| Number of pages | 4 |
| Journal | Lancet |
| Volume | 2 |
| Issue number | 8187 |
| DOIs | |
| Publication status | Published - 1980 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Adjuvant treatment with polyadenylic-polyuridylic acid (PolyA.PolyU) in operable breast cancer. / Lacour, J.; Lacour, F.; Spira, A.; Michelson, M.; Petit, J. Y.; Delage, G.; Sarrazin, D.; Contesso, G.; Viguier, J.
In: Lancet, Vol. 2, No. 8187, 1980, p. 161-164.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Adjuvant treatment with polyadenylic-polyuridylic acid (PolyA.PolyU) in operable breast cancer
AU - Lacour, J.
AU - Lacour, F.
AU - Spira, A.
AU - Michelson, M.
AU - Petit, J. Y.
AU - Delage, G.
AU - Sarrazin, D.
AU - Contesso, G.
AU - Viguier, J.
PY - 1980
Y1 - 1980
N2 - Adjuvant immunotherapy with polyadenylic-polyuridylic acid (PolyA.PolyU) was tested in a randomised trial on 300 patients with operable breast cancer, all of whom were treated by surgery with or without radiotherapy. They were randomly divided into an experimental group of 155 patients who were treated with 30 mg PolyA.PolyU intravenously per week for 6 weeks and a control group of 145 patients who received normal saline intravenously on the same schedule. The mean follow-up time was more than 50 months in both groups. The overall survival was significantly higher in the treated group (p ≤ 0.05), in whom the 5-year 'relapse-free' survival was also increased. In node-positive patients, treatment increased the relapse-free survival (p ≤ 0.03) and overall survival (p ≤ 0.07). No side-effects were noted. Thus, immunotherapy with PolyA.PolyU appears to be a simple, non-toxic, and efficient adjuvant treatment in operable breast cancer.
AB - Adjuvant immunotherapy with polyadenylic-polyuridylic acid (PolyA.PolyU) was tested in a randomised trial on 300 patients with operable breast cancer, all of whom were treated by surgery with or without radiotherapy. They were randomly divided into an experimental group of 155 patients who were treated with 30 mg PolyA.PolyU intravenously per week for 6 weeks and a control group of 145 patients who received normal saline intravenously on the same schedule. The mean follow-up time was more than 50 months in both groups. The overall survival was significantly higher in the treated group (p ≤ 0.05), in whom the 5-year 'relapse-free' survival was also increased. In node-positive patients, treatment increased the relapse-free survival (p ≤ 0.03) and overall survival (p ≤ 0.07). No side-effects were noted. Thus, immunotherapy with PolyA.PolyU appears to be a simple, non-toxic, and efficient adjuvant treatment in operable breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=0018828863&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018828863&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(80)90057-4
DO - 10.1016/S0140-6736(80)90057-4
M3 - Article
C2 - 6105336
AN - SCOPUS:0018828863
VL - 2
SP - 161
EP - 164
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 8187
ER -